Two routine blood tests flag atrial fibrillation risk

Insulin resistance, the state in which the body's cells respond poorly to insulin, is thought to play a pivotal role in the onset and progression of atrial fibrillation, an irregular heart rhythm. The problem is that measuring insulin resistance directly is impractical in routine care, which is where the triglyceride-glucose index comes in: it is a simple, low-cost surrogate calculated from two standard blood measures. If this index reliably tracks atrial fibrillation risk, it could offer a convenient tool for spotting people at higher risk before the rhythm problem appears. This review set out to quantify the strength of that relationship, covering new-onset cases, recurrence after catheter ablation, and episodes after surgery.

The researchers systematically searched five databases, including PubMed, Web of Science and three Chinese-language platforms, for studies published up to 30 September 2025. Nineteen studies met the criteria, all of them studies that followed people or compared groups rather than testing an intervention, with a combined 25,376 participants. Two reviewers independently screened the literature, extracted the data and rated study quality using an established checklist. Pooled estimates then compared TyG index levels between people with and without atrial fibrillation, and related the index, treated both as a continuous measure and in categories, to the odds of the condition, with further analyses probing how consistent the findings were.

People with atrial fibrillation had meaningfully higher TyG index levels than people without it, a pattern that held in both new-onset and post-surgical cases. Each 1-unit increase in the index was associated with a 114% rise in overall atrial fibrillation risk, and the link appeared across every subtype examined: new-onset cases, recurrence after catheter ablation, and episodes following surgery, where the association was strongest. Comparing the extremes, people in the highest TyG group carried a 211% higher adjusted risk than those in the lowest group. The individual studies varied considerably in their estimates, but sensitivity analyses suggested the overall conclusions were robust to that variation.

This pooled analysis strengthens a growing case that metabolic health and heart rhythm are intertwined, and it extends the insulin resistance story to a marker any clinic can compute from routine bloods. It cannot settle causation: because every included study followed people rather than testing an intervention, a higher TyG index could flag risk without driving it. The evidence also comes predominantly from Asian populations, and the authors are explicit that generalisability elsewhere still needs validation. Whether the index adds predictive value beyond established risk factors, and whether lowering it would change anyone's heart rhythm outlook, remain open questions for future research.

The takeaway for a general reader is that a marker of insulin resistance, derived from two blood values many people already have on file, tracks with the risk of atrial fibrillation. That is a reason to think of metabolic health as heart rhythm health, not merely a blood sugar issue. It is not a diagnosis or a prediction for any individual: the link is an association, the underlying studies could not prove cause, and the evidence base is largely Asian, so it may not translate everywhere. If the finding holds up, the appeal is practical, since the index is cheap and convenient, which is why the authors see promise for it in early risk assessment.